CRISPR Therapeutics is a biopharmaceutical company that develops gene-editing and cell therapies using CRISPR/Cas9 technology and related platforms to treat serious genetic and acquired diseases. The company's core product is CASGEVY, an ex vivo cell therapy for hemoglobinopathies that edits patients' own blood stem cells, along with a pipeline spanning in vivo gene-editing programs for cardiovascular disease and dyslipidemia, allogeneic CAR T cell therapies for hematologic malignancies and autoimmune diseases, and regenerative medicine approaches for diabetes. The company generates revenue primarily through milestone payments and royalties from strategic partnerships—notably a co-development and co-commercialization arrangement with Vertex Pharmaceuticals for CASGEVY and a collaboration with Sirius Therapeutics on RNA-based therapies—combined with product sales and licensing fees, while investing in proprietary manufacturing infrastructure to support both clinical development and commercial production.